Fiducial Markers Market

Fiducial Markers Market Outlook (2022-2032)

The global fiducial markers market is set to reach US$ 138.7 million in 2022 and further expand at a CAGR of 7.9% to end up at a market valuation of US$ 295.6 million by 2032.

Pure gold markers lead the race and are anticipated to contribute more than 55% share of the global market during the forecast period (2022-2032).

Report Attributes	Details
Fiducial Markers Market Size (2021A)	US$ 126.2 Million
Estimated Market Value (2022E)	US$ 138.7 Million
Forecasted Market Value (2032F)	US$ 295.6 Million
Global Market Growth Rate (2022-2032)	7.9% CAGR
North America Market Share (2021)	~ 27.8%
Europe Market Growth Rate (2022-2032)	~ 6.8% CAGR
United States Market Growth Rate (2022-2032)	~ 6.2% CAGR
Market Share of Top 5 Companies	~ 22.5%
Key Companies Profiled	Eckert & Ziegler BEBIG Innovative Oncology Solutions Boston Scientific IBA Dosimetry Best Medical International, Inc. IZI Medical Products Carbon Medical Technologies CIVCO alphaXRT

Sales Analysis of Fiducial Markers (2017-2021) Vs. Market Forecasts (2022-2032)

Rising prevalence of various types of cancers among the global population has created a high requirement for the identification of tumors, which has generated a huge space for fiducial markers. Intensifying prevalence of tumors, cancer, and associated diseases led to the high acceptance of fiducial markers among radiotherapy centers, hospitals, cancer institutes, and others over the historical period (2017 to 2021), which amplified the sales of fiducial markers at a CAGR of 10.3%.

Moreover, rising awareness regarding the early detection of cancer and proper treatment of radiotherapy will further fuel the sales of fiducial markers during the forecast period. Manufacturers are also focusing on enhancing the variety of fiducial markers, which will increase their demand across the globe.

Fact.MR predicts that the global fiducial markers market will be valued at US$ 295.6 million by the end of 2032, expanding at a CAGR of 7.9%.

• Short Term (2022-2025): Rising prevalence of cancer across the world will spur the sales of fiducial markers during the early forecast period.
• Medium Term (2025-2028): Government initiatives to control cancer and related diseases are anticipated to fuel the demand for fiducial markers from 2025 to 2028.
• Long Term (2028-2032): Product development and availability of a variety of fiducial markers in various sizes will generate long-term sales.

Market share analysis of fiducial markers based on product type and region. Under the product type segment, pure gold markers dominate with 62.8% market share in 2022.

Why is the Importance of Fiducial Markers Rising Rapidly?

“Intensifying Prevalence of Various Cancers Led to Upsurge in Sales of Fiducial Markers’’

Growing prevalence of various cancers such as lung cancer, breast cancer, and prostate cancer is expected to drive the demand growth for fiducial markers over the forecast period. In recent years, demand for non-invasive procedures, and radiation therapies for cancers, such as prostate cancer, has increased significantly.

Moreover, patients suffering from cancer, especially in developed regions, are progressively being treated with radiation therapies with fiducial marker placement for the particular positioning of the therapy and better and improved results post-procedure.

• As per the National Cancer Institute, cancer is one of the leading causes contributing to the high mortality rate globally. There were approximately 19.3 million new cancer cases and 9.9 million cancer-related deaths worldwide, in 2021.

Moving cancer forms such as prostate cancer and lung cancer have a high demand for fiducial marker placement before radiation therapy. The moving organs pose a high threat of improper treatment, leading to lower efficiency of the results. Increase in the prevalence of these cancers is expected to boost the growth of the fiducial markers market over the coming years.

“Growing Adoption of Radiotherapy Devices by Oncologists and Rising Demand for IGRT and SBRT Procedures”

Radiation treatment plays an extremely vital role in the management and treatment of cancer. Over the recent years, this approach has become highly contained with technological advancements and has doubled the need for radiotherapy during the last 10 years.

More than 50% of all cancer patients are expected to get radiotherapy throughout the treatment of their disease, either for symptom control or in primary management. This approach has further ensured the usage of radiotherapy fields that promise the proper treatment of tumors and the capability to heighten the radiation dose with subsequently developed outcomes and minimum toxicity.

Modern radiotherapy devices are high in demand for the irradiation procedures of organs that are not stable in position. Ensuring the exact positioning of the target structure that needs to be radiated before or during the treatment requires constant image guidance by X-ray radiography (image-guided radiotherapy IGRT) or computed tomography (CT).

Thus, due to certain combinations of novel irradiation imaging and devices, such as in-room CT or onboard imaging, tomotherapy systems are developed and are high in demand.

• The Massachusetts General Hospital (MGH) developed a system called the IRIS System that provides videos that are fluoroscopic during the entire treatment. IRIS consists of a tracking system that is capable of tracking multiple implanted markers.

The development of novel systems capable of tracking fiducial markers for tumors in moving organs is expected to boost market growth during the forecast period.

How is Market Expansion Being Dented to Some Extent?

“High Risk of Complications Associated with Fiducial Marker Placements”

The use of fiducial markers has helped in pointing the position of tumors to deliver maximum dosage while minimizing the dose delivery to the surrounding healthy tissue. Though this has proved to be of great advantage in radiation therapy procedures, there are also certain complications that fiducial markers carry.

Fiducial markers are supposed to be fixed at a particular target, however, they might move away from the originally placed position where they were implanted. A long period is required in between the implantation of markers and for them to hold the position and stabilize.

Certain risks are associated with the use of fiducial markers. Fiducial markers, when placed or used for lung cancer treatment, might lead to a complication called collapsed lung or pneumothorax. In this condition, the surgeon is required to insert a chest tube for removing the air pocket and further re-expand the lung.

Prostatitis is another complication associated with fiducial marker placement in the prostate. Approximately 32% of patients with fiducial marker implants have at least one symptom of prostatitis, i.e., fever or shivers, pain, dysuria, or frequency.

Any treatment procedure where the skin is needed to be penetrated carries a risk of infection. This possibility of infection requires antibiotic treatments. These factors are expected to hamper the growth of the fiducial markers market to some extent.

Country-wise Insights

Will Rise in Radiation Therapy in the U.S. Drive High Demand for Fiducial Markers?

The fiducial markers market in the U.S. is expected to expand at a CAGR of 6.2% from 2022 to 2032.

The dominance of the U.S. is because of a high number of radiotherapy centers, cancer institutes, and extremely developed manufacturing units. It has been observed that radiation therapy centers are rapidly rising in number due to a high number of cancer cases.

• Recently, the partnership between the National Cancer Institute (NCI) with the National Institutes of Health (NHI) is providing efficient treatment to the growing number of cancer patients in the United States.

Why is China a Highly Opportunistic Market for Fiducial Marker Manufacturers?

China has made significant advancements in the detection and treatment of several types of cancer. Manufacturers of fiducial markers have benefited immensely due to the integration of cutting-edge technologies in radiation meant for cancer.

Over the next few years, demand for fiducial markers is likely to rise as more cancer patients turn to correct treatment at an earlier stage. Hence, following these factors, China will become a highly lucrative market for fiducial marker manufacturers.

Category-wise Insights

Which Fiducial Marker is Most Widely Used across the World?

The fiducial markers market, under product type, is categorized into polymer-based markers, metal-based markers, pure gold markers, and liquid-based markers. Amongst them, pure gold fiducial markers held the largest market share of 63.1% in 2021 and are expected to witness a CAGR of 7.5% during the forecast years of 2022-2032.

Pure gold fiducial markers have gained high popularity among all the markers and are expected to hold this position during the forecast period. Intraprostatic gold fiducial markers ensure that highly accurate and precise image-guided radiation therapy can be administered to patients suffering from prostate cancer. These are also highly preferred by radiologists in treating lung, breast, and other types of cancers.

Patients with prostate cancer receive extremely accurate and precise image-guided radiation therapy with the use of intraprostatic gold fiducial markers.

Why Has Photon Therapy Gained Wide Prominence in the Fiducial Markers Market?

In terms of modality, the market is segmented into photon therapy, proton therapy, tomotherapy, and cyberknife. Out of these, the photon therapy segment holds a majority of the share in the global market. It is anticipated to follow the same trend during the forecast period. The segment is projected to account for 50.8% share of the market by 2032.

The dominance of photon therapy is due to its high demand from varied end-users such as radiotherapy centers, hospitals, and others. Photon therapy attacks tumors by preventing cancer cells from growing and dividing, and hence, it is highly desirable due to its efficiency.

Competitive Landscape

Prominent fiducial marker manufacturers are Eckert & Ziegler BEBIG, Innovative Oncology Solutions, Boston Scientific, IBA Dosimetry, Best Medical International, Inc., IZI Medical Products, Carbon Medical Technologies, CIVCO, alphaXRT, Nanovi A/S, and Stellar Medical.

Most companies producing fiducial markers are working towards expanding their product portfolios. However, the most significant approach towards increasing the customer pool is through the marketing of the product through online portals. Making the product available on online channels is also expected to drive the growth of the market.

• In 2020, Innovative Oncology Solutions launched its new range of fiducial markers - SBRT Immobilization, Supine Breast & Thorax Positioning, and others.
• In 2020, CIVCO launched its new extensive range of fiducial markers - such as Solstice™ MR SRS Immobilization System, Monarch™ Vac-Lok™ Options, and others.

Fact.MR has provided detailed information about the price points of key manufacturers of fiducial markers positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

Segmentation of Fiducial Marker Industry Research

• By Product Type :

  • Polymer-based Markers
  • Metal-based Markers
  • Pure Gold Markers
  • Liquid-based Markers

• By Modality :

  • Photon Therapy
  • Proton Therapy
  • Tomotherapy
  • Cyberknife

• By Disease Site :

  • Head & Neck
  • Breast
  • Lung
  • Abdomen
  • Prostate
  • Kidney
  • Cervix or Other Gynaecologic Organs

• By End User :

  • Hospitals
  • Cancer Research Institutes
  • Radiotherapy Centers

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & ASEAN
  • Oceania
  • MEA